Online citations, reference lists, and bibliographies.
← Back to Search

'Stealth' Lipid-based Formulations: Poly(ethylene Glycol)-mediated Digestion Inhibition Improves Oral Bioavailability Of A Model Poorly Water Soluble Drug.

O. Feeney, H. Williams, C. Pouton, C. H. Porter
Published 2014 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
For over 20years, stealth drug delivery has been synonymous with nanoparticulate formulations and intravenous dosing. The putative determinants of stealth in these applications are the molecular weight and packing density of a hydrophilic polymer (commonly poly(ethylene glycol) (PEG)) that forms a steric barrier at the surface of the nanoparticle. The current study examined the potential translation of the concepts learned from stealth technology after intravenous administration to oral drug delivery and specifically, to enhance drug exposure after administration of oral lipid-based formulations (LBFs) containing medium-chain triglycerides (MCT). MCT LBFs are rapidly digested in the gastrointestinal tract, typically resulting in losses in solubilisation capacity, supersaturation and drug precipitation. Here, non-ionic surfactants containing stealth PEG headgroups were incorporated into MCT LBFs in an attempt to attenuate digestion, reduce precipitation risk and enhance drug exposure. Stealth capabilities were assessed by measuring the degree of digestion inhibition that resulted from steric hindrance of enzyme access to the oil-water interface. Drug-loaded LBFs were assessed for maintenance of solubilising capacity during in vitro digestion and evaluated in vivo in rats. The data suggest that the structural determinants of stealth LBFs mirror those of parenteral formulations, i.e., the key factors are the molecular weight of the PEG in the surfactant headgroup and the packing density of the PEG chains at the interface. Interestingly, the data also show that the presence of labile ester bonds within a PEGylated surfactant also impact on the stealth properties of LBFs, with digestible surfactants requiring a PEG Mw of ~1800g/mol and non-digestible ether-based surfactants ~800g/mol to shield the lipidic cargo. In vitro evaluation of drug solubilisation during digestion showed stealth LBFs maintained drug solubilisation at or above 80% of drug load and reduced supersaturation in comparison to digestible counterparts. This trend was also reflected in vivo, where the relative bioavailability of drug after administration in two stealth LBFs increased to 120% and 182% in comparison to analogous digestible (non-stealth) formulations. The results of the current study indicate that self-assembled "stealth" LBFs have potential as a novel means of improving LBF performance.
This paper references
Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after 227 O.M
C.J.H. Porter (2014)
10.1016/j.ejpb.2011.03.019
Inhibition of lipase-catalyzed hydrolysis of emulsified triglyceride oils by low-molecular weight surfactants under simulated gastrointestinal conditions.
Y. Li (2011)
10.1016/S0169-409X(96)00489-9
Influence of lipolysis on drug absorption from the gastro-intestinal tract
Karen J. MacGregor (1997)
10.1016/0014-5793(91)80699-4
Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo
A. Mori (1991)
Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity, Biochim
V. P. Torchilin (1994)
Classification of surface-active agents by "HLB"
W. C. Griffin (1946)
10.1016/j.ejps.2010.07.005
Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes.
Anne Christiansen (2010)
10.1016/J.FOODHYD.2010.09.007
Investigating the effect of surfactants on lipase interfacial behaviour in the presence of bile salts
A. Torcello-Gómez (2011)
10.1016/S0378-5173(98)00054-4
Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine
Shui-Mei Khoo (1998)
10.1016/S0169-409X(96)00490-5
Formulation of self-emulsifying drug delivery systems
C. Pouton (1997)
10.1002/jps.24067
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.
H. Williams (2014)
10.1016/S1056-8719(00)00107-6
Drug-like properties and the causes of poor solubility and poor permeability.
C. Lipinski (2000)
10.1007/s11095-009-9906-2
In Vitro Gastrointestinal Lipolysis of Four Formulations of Piroxicam and Cinnarizine with the Self Emulsifying Excipients Labrasol® and Gelucire® 44/14
S. Fernandez (2009)
10.1016/0005-2736(91)90201-I
Pharmacokinetics of stealth versus conventional liposomes: effect of dose.
T. Allen (1991)
10.1016/j.jconrel.2012.02.027
In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS).
N. Thomas (2012)
10.1002/anie.201200409
Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced oral drug absorption.
A. Tan (2012)
10.1021/mp7001208
The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
L. M. Kaminskas (2008)
10.1002/jps.23205
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations.
H. Williams (2012)
10.1016/0378-5173(85)90081-X
Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification
C. Pouton (1985)
10.1021/mp9002442
Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems.
A. Tan (2010)
10.1515/9783111576855-015
J
Seguin Hen (1824)
10.1002/jps.21659
Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution.
K. Mohsin (2009)
10.1016/J.EJPB.2006.10.005
Correlation between digestion of the lipid phase of smedds and release of the anti-HIV drug UC 781 and the anti-mycotic drug enilconazole from smedds.
C. Goddeeris (2007)
10.1021/BK-1997-0680.CH001
Introduction to Chemistry and Biological Applications of Poly(ethylene glycol)
S. Zalipsky (1997)
10.1021/mp300331z
Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
H. Williams (2012)
10.1124/DMD.30.10.1059
Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys.
S. Balani (2002)
10.1023/B:PHAM.0000036914.22132.cc
Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation
C. H. Porter (2004)
10.1038/nrd2197
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
C. H. Porter (2007)
10.1023/B:PHAM.0000016282.77887.1f
Drug Solubilization Behavior During in Vitro Digestion of Simple Triglyceride Lipid Solution Formulations
A. Kaukonen (2004)
10.3109/08982109409037068
Why do Polyethylene Glycol-Coated Liposomes Circulate So Long?: Molecular Mechanism of Liposome Steric Protection with Polyethylene Glycol: Role of Polymer Chain Flexibility
V. P. Torchilinl (1994)
10.1021/mp500197b
An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.
M. U. Anby (2014)
10.1016/j.ijpharm.2011.12.025
Controlling lipolysis through steric surfactants: new insights on the controlled degradation of submicron emulsions after oral and intravenous administration.
Miguel Wulff-Pérez (2012)
10.1002/jps.23054
Influence of lipid composition and drug load on the In Vitro performance of self-nanoemulsifying drug delivery systems.
N. Thomas (2012)
10.1002/JPS.2600640513
Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans.
T. R. Bates (1975)
10.1023/A:1015921702258
Structure/Effect Studies of Fatty Acid Isomers as Skin Penetration Enhancers and Skin Irritants
B. Aungst (2004)
10.1016/S0168-3659(03)00201-3
Polymer vesicles in vivo: correlations with PEG molecular weight.
P. Photos (2003)
10.1021/mp200352q
Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study.
S. Li (2012)
10.1124/PR.112.005660
Strategies to Address Low Drug Solubility in Discovery and Development
H. Williams (2013)
10.1023/B:PHAM.0000016235.32639.23
Solubilizing Excipients in Oral and Injectable Formulations
R. Strickley (2004)
10.1002/jps.22226
Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate.
P. Sassene (2010)
10.1007/s11095-010-0362-9
Effects of Surfactants on Lipase Structure, Activity, and Inhibition
Vincent Delorme (2010)
10.1016/0005-2736(94)90003-5
Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity.
V. Torchilin (1994)
10.3109/02652049809006831
Polymer-coated long-circulating microparticulate pharmaceuticals.
V. Torchilin (1998)
10.2165/00003495-199700544-00005
Polyethylene Glycol-Coated (Pegylated) Liposomal Doxorubicin
A. Gabizon (2012)
10.1023/A:1018987928936
Self-Emulsifying Drug Delivery Systems: Formulation and Biopharmaceutic Evaluation of an Investigational Lipophilic Compound
S. Charman (2004)
10.1211/jpp.58.6.0011
Examination of the impact of a range of Pluronic surfactants on the in‐vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone
L. Sek (2006)
10.1021/mp300164u
Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems.
M. U. Anby (2012)
10.1002/JPS.20039
Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine.
C. H. Porter (2004)
10.1515/9783111576855-012
G
G.V.T.V. Weerasooriya (1824)
10.1016/j.bbalip.2008.05.006
Lipolysis of the semi-solid self-emulsifying excipient Gelucire 44/14 by digestive lipases.
S. Fernandez (2008)
10.1002/JPS.21246
Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs.
Jean F Cuiné (2008)
10.1016/S0927-7765(99)00156-3
'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption.
Gref (2000)
10.1002/JPS.10554
Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach.
Greg A Kossena (2004)
10.1016/J.ADDR.2007.10.014
Enhancing intestinal drug solubilisation using lipid-based delivery systems.
C. H. Porter (2008)
10.1021/BK-1991-0467.CH027
New Polyethylene Glycols for Biomedical Applications
J. M. Harris (1991)



This paper is referenced by
10.2147/IJN.S257269
The Influence of Nanoparticle Properties on Oral Bioavailability of Drugs
Yuanyuan Wang (2020)
10.3109/03639045.2014.972412
In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract
V. Jannin (2015)
10.1039/c9bm00873j
Slowing down lipolysis significantly enhances the oral absorption of intact solid lipid nanoparticles.
Z. Yu (2019)
10.1016/j.nano.2020.102237
Advances in next-generation lipid-polymer hybrid nanocarriers with emphasis on polymer-modified functional liposomes and cell-based-biomimetic nanocarriers for active ingredients and fractions from Chinese medicine delivery.
Y. Liu (2020)
10.1039/c7bm01096f
The effect of surface charge on oral absorption of polymeric nanoparticles.
X. Du (2018)
10.1016/j.ejmech.2016.04.016
Semi-synthesis and antiproliferative evaluation of PEGylated pentacyclic triterpenes.
M. Medina-O’Donnell (2016)
10.1039/C5RA28018D
Enhanced hepatic-targeted delivery via oral administration using nanoliposomes functionalized with a novel DSPE–PEG–cholic acid conjugate
Y. Li (2016)
10.1016/j.ejps.2020.105452
Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across PermeapadⓇ membrane and in vivo absorption.
Alexandra-Roxana Ilie (2020)
10.1016/J.JDDST.2018.10.007
Solid lipid nanoparticles modified with amphipathic chitosan derivatives for improved stability in the gastrointestinal tract
Suping Qiu (2018)
10.1021/acs.langmuir.7b03043
Degree of Unsaturation and Backbone Orientation of Amphiphilic Macromolecules Influence Local Lipid Properties in Large Unilamellar Vesicles.
Alysha Moretti (2017)
10.9734/JPRI/2017/36872
Solubility Enhancement of a BCS Class II Drug Using Granulated Fumed Silica as an Adsorbent
Sawani D. Talekar (2017)
10.1016/j.xphs.2018.11.028
A Nonionic Polyethylene Oxide (PEO) Surfactant Model: Experimental and Molecular Dynamics Studies of Kolliphor EL.
Estelle J A Suys (2019)
10.1039/c5nr07474f
Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery.
Xiongwei Hu (2016)
10.1002/jps.24634
In Situ Lipolysis and Synchrotron Small-Angle X-ray Scattering for the Direct Determination of the Precipitation and Solid-State Form of a Poorly Water-Soluble Drug During Digestion of a Lipid-Based Formulation.
J. Khan (2016)
10.26180/5DEA0300E177B
Oral lipid-based drug delivery: Inhibiting and eliminating digestion to improve absorption of poorly soluble drugs.
O. Feeney (2019)
10.1177/0885328215578111
Functional liposomes in the cancer-targeted drug delivery
D. Tila (2015)
10.1016/j.jcis.2020.04.015
Modulating the release of pharmaceuticals from lipid cubic phases using a lipase inhibitor.
Michele Dully (2020)
10.1016/j.addr.2016.03.011
How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?
H. Malhaire (2016)
10.1021/acsami.6b15004
Core (Polystyrene)-Shell [Poly(glycerol monomethacrylate)] Particles.
A. McKenzie (2017)
10.1016/j.ajps.2018.03.001
Enhanced digestion inhibition and mucus penetration of F127-modified self-nanoemulsions for improved oral delivery☆
Wenyi Song (2018)
10.1016/j.ijpharm.2016.03.055
Novel nanoemulsion based lipid nanosystems for favorable in vitro and in vivo characteristics of curcumin.
Kun Wan (2016)
10.1517/17425247.2016.1151872
Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery
Shasha Rao (2016)
10.1016/j.jconrel.2017.03.393
In vitro and in vivo performance of monoacyl phospholipid‐based self‐emulsifying drug delivery systems
T. Tran (2017)
10.1021/acs.molpharmaceut.7b00660
Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
Claire L McEvoy (2017)
10.1016/j.addr.2015.09.012
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.
J. Suk (2016)
10.1080/17425247.2016.1218462
From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS)
Fiza Ur Rehman (2017)
10.1016/j.ijpharm.2015.03.044
Novel semisolid SNEDDS based on PEG-30-di-(polyhydroxystearate): Progesterone incorporation and in vitro digestion.
T. Hassan (2015)
10.1016/j.colsurfb.2015.03.036
Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: Chain length of poly (ethylene glycol) corona.
Zhenbao Li (2015)
10.2147/IJN.S73340
Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation
X. Zhang (2014)
10.1016/j.foodchem.2017.06.137
Control of the gastrointestinal digestion of solid lipid nanoparticles using PEGylated emulsifiers.
C. Ban (2018)
10.1208/s12248-016-0036-6
Inclusion of Digestible Surfactants in Solid SMEDDS Formulation Removes Lag Time and Influences the Formation of Structured Particles During Digestion
K. Vithani (2016)
10.2147/IJN.S87471
Nanoemulsions as novel oral carriers of stiripentol: insights into the protective effect and absorption enhancement
R. Lu (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar